DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA): $97.75

0.31 (+0.32%)

POWR Rating

Component Grades














  • Stability is the dimension where DVA ranks best; there it ranks ahead of 86.31% of US stocks.
  • DVA's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • DVA ranks lowest in Momentum; there it ranks in the 17th percentile.

DVA Stock Summary

  • Davita Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 98.16% of US listed stocks.
  • For DVA, its debt to operating expenses ratio is greater than that reported by 84.95% of US equities we're observing.
  • DVA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 97.12% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Davita Inc, a group of peers worth examining would be LAMR, SP, IAA, CLW, and TRU.
  • DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.

DVA Valuation Summary

  • In comparison to the median Healthcare stock, DVA's price/sales ratio is 68.42% lower, now standing at 1.2.
  • DVA's EV/EBIT ratio has moved up 6.3 over the prior 243 months.
  • Over the past 243 months, DVA's price/sales ratio has gone up 0.1.

Below are key valuation metrics over time for DVA.

Stock Date P/S P/B P/E EV/EBIT
DVA 2021-08-31 1.2 10.7 15.9 17.0
DVA 2021-08-30 1.2 10.8 15.9 17.1
DVA 2021-08-27 1.2 10.7 15.9 17.0
DVA 2021-08-26 1.2 10.7 15.8 17.0
DVA 2021-08-25 1.2 10.7 15.9 17.0
DVA 2021-08-24 1.2 10.8 16.0 17.1

DVA Growth Metrics

    The 4 year cash and equivalents growth rate now stands at 42.93%.
  • Its 5 year price growth rate is now at 7.69%.
  • Its 4 year price growth rate is now at 7.69%.
DVA's revenue has moved up $320,278,000 over the prior 34 months.

The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 11,618.8 1,930.876 978.45
2021-09-30 11,580.15 1,885.786 964.75
2021-06-30 11,565.9 1,801.561 863.67
2021-03-31 11,529.37 1,772.951 771.452
2020-12-31 11,550.6 1,979.028 773.642
2020-09-30 11,543.87 2,174.76 844.74

DVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVA has a Quality Grade of B, ranking ahead of 81.19% of graded US stocks.
  • DVA's asset turnover comes in at 0.661 -- ranking 45th of 81 Healthcare stocks.
  • LHCG, NTRA, and CHE are the stocks whose asset turnover ratios are most correlated with DVA.

The table below shows DVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.661 0.312 0.082
2021-06-30 0.666 0.314 0.078
2021-03-31 0.650 0.310 0.074
2020-12-31 0.651 0.308 0.077
2020-09-30 0.648 0.313 0.083
2020-06-30 0.643 0.310 0.082

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.11 Average Broker Recommendation 2 (Hold)

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $97.75 52-week high $136.48
Prev. close $97.44 52-week low $91.73
Day low $97.31 Volume 89,192
Day high $98.32 Avg. volume 674,280
50-day MA $109.35 Dividend yield N/A
200-day MA $112.44 Market Cap 9.25B

DaVita Inc. (DVA) Company Bio

DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Latest News Stream

Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream

Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

7 Berkshire Hathaway Stock Picks to Buy If You Wanna Be Like Warren

With market uncertainty ratcheting up, and more speculative names under pressure, now may be the time to cycle into Warren Buffett stocks.

Thomas Niel on InvestorPlace | February 25, 2022

DaVita study suggests J&J, Pfizer/BioNTech COVID vaccines at parity for kidney patients

DaVita (NYSE:DVA) said a study suggested that dialysis patients who received Johnson & Johnson's (NYSE:JNJ) adenovirus vector-based COVID-19 vaccine were found to have similar rates of breakthrough infection, hospitalization and mortality as dialysis patients who received an mRNA-based vaccine from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). The company said the DaVita...

Seeking Alpha | February 17, 2022

DaVita Clinical Research Study Finds Efficacy of Common COVID-19 Vaccines at Parity for Kidney Patients

Dialysis patients who received an adenovirus vector-based COVID-19 vaccine (Johnson & Johnson) were found to have similar rates of breakthrough infection, hospitalization and mortality as dialysis patients who received an mRNA-based vaccine (Pfizer/BioNTech), according to a DaVita Clinical Research (DCR) study published online ahead of print by the Journal of the American Society of Nephrology.

Yahoo | February 17, 2022

DaVita Kidney Care Appoints New Chief Medical Officer of Home Modalities

DaVita Kidney Care today announced Dr. Mihran Naljayan as chief medical officer (CMO) of Home Modalities.

Yahoo | February 16, 2022

DaVita expands paid leave to support teammates choosing to be living organ donors

In honor of National Donor Day—and every living organ donor—DaVita announced it increased paid leave for organ donation to four consecutive weeks for benefits-eligible teammates (employees) who donate their bone marrow, liver or kidney.

Yahoo | February 14, 2022

Read More 'DVA' Stories Here

DVA Price Returns

1-mo -9.53%
3-mo -14.70%
6-mo 0.47%
1-year -18.99%
3-year 108.33%
5-year 50.97%
YTD -14.07%
2021 -3.10%
2020 56.47%
2019 45.80%
2018 -28.78%
2017 12.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4745 seconds.